| Identification | Back Directory | [Name]
N-Cyclohexyl-2-piperazin-1-yl-acetamide | [CAS]
64204-55-3 | [Synonyms]
C/63
Esaprazole
Esaprazole, 10 mM in DMSO
N-Cyclohexyl-2-piperazin-1-yl-ace
N-Cyclohexyl-1-piperazineacetamide
1-piperazineacetamide, N-cyclohexyl-
N-Cyclohexyl(piperazin-1-yl)acetamide
N-Cyclohexyl-2-piperazin-1-yl-acetamide
N-cyclohexyl-2-piperazin-1-ylacetamide dihydrochloride
{[(Piperazin-1-yl)acetyl]amino}cyclohexane, 1-[2-(Cyclohexylamino)-2-oxoethyl]piperazine | [Molecular Formula]
C12H23N3O | [MDL Number]
MFCD00865680 | [MOL File]
64204-55-3.mol | [Molecular Weight]
225.33 |
| Safety Data | Back Directory | [Hazard Codes ]
Xi | [HazardClass ]
IRRITANT | [HS Code ]
2933599590 | [Toxicity]
LD50 in mice (mg/kg): 1974 orally; 271 i.v.; in rats (mg/kg): 3900 orally (Corvi-Mora) |
| Hazard Information | Back Directory | [Uses]
Esaprazole (Hexaprazole) is an antiulcer agent that has the effect of promoting the healing of peptic ulcer. Esaprazole can inhibit the secretion of gastric acid and pepsin[1]. | [in vivo]
Esaprazole (50-450 mg/kg; intraduodenal administration; single dose) can inhibit the secretion of gastric acid and pepsin in a dose-dependent manner in Wistar rats. Moreover, Esaprazole (25, 50, and 100 mg/kg; intraperitoneal injection; single dose) can also inhibit the hypersecretion of acid induced by Bethanechol (HY-B0406) (500 μg/kg/h) and the acid secretory response induced by vagal stimulation[1]. | [References]
[1] Blandizzi C, et al. Gastric antisecretory effects of esaprazole in rats. Digestion. 1992;51(4):226-232. DOI:10.1159/000200902 |
|
| Company Name: |
Matrix Scientific
|
| Tel: |
803 788-9494 All other calls |
| Website: |
www.matrixscientific.com |
|